The limited effectiveness of rituximab plus intravenous immunoglobulin (IVIG) in desensitization may be due to incomplete B cell depletion. Obinutuzumab is a type 2 anti-CD20 antibody that induces increased B cell depletion relative to rituximab and may therefore be more effective for desensitization. This open-label phase 1b study assessed the safety, pharmacokinetics, and pharmacodynamics of obinutuzumab in highly sensitized patients with end-stage renal disease. Patients received 1 (day 1, n = 5) or 2 (days 1 and 15; n = 20) infusions of 1000-mg obinutuzumab followed by 2 doses of IVIG on days 22 and 43. Eleven patients received additional obinutuzumab doses at the time of transplant and/or at week 24. The median follow-up duration was 9.4 months. Obinutuzumab was well tolerated, and most adverse events were grade 1-2 in severity. There were 11 serious adverse events (SAEs) in 9 patients (36%); 10 of these SAEs were infections and 4 occurred after kidney transplant. Obinutuzumab plus IVIG resulted in profound peripheral B cell depletion and appeared to reduce B cells in retroperitoneal lymph nodes.
| INTRODUC TI ON
Antihuman leukocyte antigen (HLA) alloantibodies are a major barrier to successful kidney transplantation in patients with end-stage renal disease (ESRD) and can lead to substantial reductions in renal allograft survival. 1, 2 HLA-sensitized patients represent approximately 30% of patients on the waitlist for kidney transplant 3 and historically have faced longer wait times for a suitable donor graftas well as inferior long-term outcomes following transplant-than patients who are not sensitized. [4] [5] [6] To improve access to transplant for this population, several approaches have been attempted, including treatment with the anti-CD20 monoclonal antibody rituximab to deplete CD20 + B cells, which play a central role in humoral immunity.
A seminal study combining rituximab with intravenous immunoglobulin (IVIG) reported reduction of the level of sensitization (as measured by panel reactive antibodies [PRA] ) that enabled most patients (16/20; 80%) to receive a kidney graft with excellent posttransplant outcomes. 7 These effects were not replicated in subsequent similarly uncontrolled case series, however, raising the question whether inconsistent effects might be due to the patient populations studied. Alternatively, this could be due to incomplete tissue B cell depletion. [8] [9] [10] [11] [12] B cell depletion would be expected to reduce anti-HLA alloantibody levels if anti-HLA alloantibodies were produced by a plasma-cell population that required ongoing replenishment by production of new plasmablasts from memory B cell populations.
Despite enabling peripheral blood B cell depletion, rituximab incompletely depletes lymphoid organ B cells. 8, [11] [12] [13] Although the exact reasons for the inconsistent effects of rituximab on desensitization are not known, one hypothesis is that achieving more extensive B cell depletion than is achieved with rituximab, particularly in tissue, may improve results in highly sensitized patients with ESRD.
Obinutuzumab is a glycoengineered type 2 anti-CD20 monoclonal antibody that has been shown to be more efficacious than rituximab in depleting B cells in peripheral blood and lymphoid tissue, in both animal models and patients with chronic lymphocytic leukemia (CLL); 13, 14 in particular, significantly greater B cell depletion in bone marrow was observed with obinutuzumab than with rituximab in patients with CLL. 14 We hypothesized that the greater capacity of obinutuzumab to induce depletion of tissue-resident B cells may overcome the limitations of rituximab and provide greater anti-HLA antibody reduction in highly sensitized patients. We present here the results of an openlabel study of obinutuzumab in combination with high-dose IVIG to evaluate the safety, tolerability, and pharmacokinetics (PK) of obinutuzumab and its effect on B cell depletion and anti-HLA antibodies in highly sensitized patients with ESRD awaiting transplant.
| MATERIAL S AND ME THODS

| Study design
THEORY was a phase 1b, open-label, sequential 2-cohort study comparing single and repeated doses of obinutuzumab with high-dose IVIG in highly sensitized candidates for renal transplant in the United States (NCT02586051). Twenty-five patients were enrolled between November 2015 and August 2016 at 7 centers in the United States. Patients in cohort 1 received a single intravenous infusion of 1000-mg obinutuzumab on day 1 followed by 2 g/kg IVIG (maximum 140 g) at weeks 3 and 6. Following a 28-day observation period for adverse events (AEs), patients were enrolled in cohort 2 and received 1000-mg obinutuzumab infusions on days 1 and 15, and an optional 1000-mg infusion at week 24, plus an IVIG regimen identical to cohort 1. All patients were monitored for 12 months following the last obinutuzumab infusion ( Figure S1 ).
Patients who underwent kidney transplant (per local center practices) before week 52 received an additional obinutuzumab infusion at the time of transplant (peritransplant) and 24 weeks after transplant and were followed up for 52 weeks after their last obinutuzumab dose to further assess safety and tolerability. The transplant population is still being followed at the time of this report and will be described separately. Analyses are based on the data available as of March 10, 2017, unless otherwise stated. Statistical methods are described in the Data S1.
This study was conducted in accordance with local institutional review board ethical standards, good clinical practices, and the Declaration of Helsinki. All patients provided written informed consent before study participation.
| Study objectives
The primary objective assessed the safety and tolerability of the obinutuzumab/IVIG regimen at week 24 of the desensitization phase. The secondary objective characterized the PK and pharmacodynamic (PD) profiles of obinutuzumab. PD markers included peripheral blood CD19 + B cells and anti-HLA alloantibodies.
Exploratory objectives aimed to quantify the impact of obinutuzumab on sensitization as measured by the number of unacceptable antigens (UAs), the calculated panel reactive antibody (CPRA) score, and anti-HLA antibodies strength at week 24, as well as posttransplant estimated glomerular filtration rate (eGFR), calculated using Chronic Kidney Disease Epidemiology Collaboration equation. 15 
| Patient selection
Patients were 18-65 years old, had ESRD, were awaiting renal transplant, and had both a history of sensitizing events and CPRA ≥ 50% at screening. CPRA was calculated based on input from the local transplant team and incorporated site-generated data (Data S1).
Patients were required to be United Network for Organ Sharing listed for a deceased donor kidney transplant and have an estimated high likelihood of receiving an offer 12-18 months after screening, as evidenced by presence on ≥1 match run for a deceased donor kidney during the past year or CPRA ≥98%. The number of patients who had received a prior transplant was capped at 6. Further details are available in the Data S1.
| Blood B cell enumeration and measurement in tissue
B cells were measured using a validated 6-color, lyse/no-wash flow cytometry assay. Cells from peripheral blood or lymph nodes were stained with antibodies to identify B cells. Total B cells were defined using light scatter characteristics, CD45 + , CD3 − /CD14 − , CD56 − / CD33 − , and CD19 + . Further details are available in the Data S1.
| Anti-HLA antibodies
For patient clinical management, participating sites continued to use antibody screening data generated at their local laboratories. Serum samples were collected in parallel for central study analyses. Anti-HLA alloantibodies were quantified using Luminex-based singleantigen bead (SAB) Lab Screen assays at the UCLA Immunogenetics Center (Clinical Laboratory Improvement Amendments certified and American Society for Histocompatibility and Immunogenetics accredited). Anti-HLA serum reactivity was calculated by measurement of HLA antibody bound to each bead, expressed as mean fluorescence intensity (MFI). 16 The desensitization assessment scientific panel and criteria for UAs are described in the Data S1.
| Laboratory assessments
All laboratory safety assessments, including IgA, IgM, IgG, vaccination titers, and the schedule of assessments, are depicted in Tables S1 and S2.
| RE SULTS
| Patient disposition and baseline characteristics
Twenty-five patients were enrolled and received ≥1 dose of obinutuzumab (cohort 1, n = 5; cohort 2, n = 20). As of the data cutoff of March 10, 2017, 8 patients had received a transplant (cohort 1, n = 1; cohort 2, n = 7). One of the 7 patients in cohort 2 was withdrawn before day 15 because the patient received a transplant 6 days after the baseline visit and therefore received only 1 dose of obinutuzumab and no IVIG infusion; this patient was followed for safety only and not included in the exploratory efficacy assessment. Overall, 6 of the 8 patients had received 2 doses of obinutuzumab prior to transplantation, and the remaining 2 received only 1 dose each ( Figure 1 ). Per protocol, patients undergoing transplant received additional doses of obinutuzumab around the time of and 24 weeks after renal transplant. Patient baseline characteristics are presented in Table 1 . Whereas serum IgA and IgM levels slightly decreased from baseline to week 12 to a mean (median) of 96.6% (95.6%) and 91.7% (87.9%), respectively, serum IgG increased to a mean (median) of 114% (111%). From baseline to week 24, IgA, IgM, and IgG decreased to a mean (median) of 93.3% (86.5%), 94.0% (68.2%), and 88.0% (88.6%), respectively. Changes in cohort 1 and cohort 2 were comparable. No correlation between the onset of infection and immunoglobulin levels was observed.
| Safety
Vaccination titers were stable throughout the study. There were no changes in serostatus of antibodies to mumps, rubella, or varicella-zoster. Antipneumococcal capsular polysaccharide and antitetanus toxoid antibody titers fluctuated, but the median concentration did not change between screening and week 24 and all titers remained in the protective range. 
| Pharmacodynamic analyses
| Peripheral B cells
| CD19 + B cells in lymph nodes
In patients who received a transplant, the level of CD19 + B cells in retroperitoneal lymph nodes procured at time of transplant appeared reduced in the majority (5/7) relative to observational comparator cohorts of peritransplant patients who had not been exposed to obinutuzumab (Data S1; Figure 3 ). The 2 patients whose B cell percentages in lymph nodes were not reduced relative to nonstudy dilution (Data S1). There were no obvious sensitizing or infectious events that coincided with the signal increase in these 6 patients. (range, −1.31% to +5.11%) ( Figure 5D ).
| Anti-HLA antibody profile
| Unacceptable antigens and CPRA over time
| On-study kidney transplants
At the time of the primary analysis, 8 of the 25 patients (cohort 
| Pharmacokinetic analyses
PK data were available from all 25 patients using limited PK sampling. Obinutuzumab serum concentration data were analyzed using nonlinear mixed effect modeling. 17 The concentration-time course of obinutuzumab was well described by a linear 2-compartment PK model with time-dependent clearance. Clearance and volume of distribution parameters increased with body weight and were higher in male patients, although data from only 3 male patients were included; body weight and gender are known to affect obinutuzumab PK in hematological indications. 18 Main PK parameters following 2 doses of 1000-mg obinutuzumab (cohort 2) are shown in Table 3 .
In the population PK model in patients with ESRD, after the last dose in cohort 2 the estimated median C max was 409 μg/mL and AUC 168d was 11 981 μg × day/mL. Following IV administration, the median volume of distribution at steady state was 3.77 L, which approximates total blood volume, indicating that distribution was largely restricted to plasma and interstitial fluid. The clearance of obinutuzumab was approximately 0.18, 0.13, and 0.09 L/d at time 0, month 6, and month 12, respectively.
The 1 male patient in cohort 2 with antidrug antibody who had low exposure had rapid recovery of peripheral B cells ( Figure 2 ).
| D ISCUSS I ON
At the time this study was designed, highly sensitized patients with ESRD made up 30% of the kidney transplant waitlist. These patients have longer wait times for a suitable donor graft and inferior longterm outcomes following transplant than patients who are not sensitized. [4] [5] [6] 19 With no approved pharmacological therapy to reduce the degree of sensitization before transplant, new approaches for effective desensitization to control HLA-specific alloantibody production remain an unmet medical need. This study assessed the safety, PK/ PD, and exploratory efficacy of obinutuzumab/IVIG in highly sensi- Rituximab has had limited success in reducing anti-HLA antibody levels in patients with ESRD, with some uncontrolled studies showing no effect, [8] [9] [10] [11] [12] possibly due to incomplete tissue B cell depletion. 8, [11] [12] [13] The current study was carried out based on the improved B cell depletion observed in blood and secondary lymphoid organs with obinutuzumab compared with rituximab. 13, 14 Obinutuzumab resulted in extensive peripheral blood and tissue B cell depletion;
however, anti-HLA antibody reductions were inconsistent and limited. Although a few patients did display pronounced reduction in some anti-HLA reactivities, the results of this study do not suggest a clinically meaningful desensitizing effect across most patients.
The fact that depletion of CD20 + B cells alone does not significantly affect HLA antibody production indicates that HLA antibodies are produced by CD20 − , mature, long-lived plasma cells. These plasma cells may not depend on constant replenishment from a CD20 + B cell population but rather may exist for the remainder of the host's life, only gradually outcompeted by newly produced plasma cells.
Consistent with this, vaccination Ig titers were also not significantly affected by obinutuzumab.
Based on these findings, one may expect plasma-cell targeting to have greater effects on the reduction of anti-HLA antibody titers. However, despite its ability to significantly deplete bone marrow plasma cells, treatment with proteasome inhibitors (PI) results in variable reductions in anti-HLA antibodies in transplant patients and autoantibodies in patients with autoimmune disease, [21] [22] [23] [24] likely due to the frequent occurrence of rebound in antibody production. 25 Potential mechanisms underlying these observations have been recently described in Rhesus macaques by Kwun et al 26 over bortezomib. 27, 28 Alternatively, future therapeutic regimens could combine obinutuzumab with antibodies targeting plasma-cell survival factors like IL-6, B cell activating factor (BAFF), and/or a proliferation-inducing ligand (APRIL). 29 The benefit of suppressing anti-HLA alloantibodies via sustained plasma-cell depletion with combination therapy will need to be weighed against the safety risk of depleting protective humoral response and vaccinations.
HLA alloantibodies were assessed in a central laboratory using a state-of-the-art fluorescence-based SAB-based assay. In contrast, earlier positive studies with rituximab/IVIG or IVIG alone had employed a cytotoxic lymphocyte panel assay and suggested more meaningful and consistent desensitization based on PRA. 7, 30 Although antibody strength as reflected in SAB MFI signals is typically considered a prerequisite for identifying clinically relevant anti-HLA alloantibodies, assessing desensitization based on all positive MFI reactivities may neglect a clinically meaningful desensitizing effect on specific alloantigens. The ideal endpoint in desensitization remains to be defined because each technique for evaluation of efficacy presents challenges and opportunities; this difficulty in finding an appropriate endpoint is common in transplant. 31 The main limitations of this study are the lack of an IVIG control arm and the small study size, which do not allow for a more clinically meaningful 
